S42.266S Nondisplaced fracture of lesser tuberosity of unspecified humerus, sequela

Name of the Condition

• Nondisplaced fracture of lesser tuberosity of unspecified humerus, sequela (ICD Code: S42.266S)

Summary

This condition represents a nondisplaced fracture of the lesser tuberosity, a bony prominence on the humerus near the shoulder joint, occurring during the sequela phase. The sequela phase indicates residual effects following the acute injury, where the fracture has healed but may still impact function or require ongoing management. The lesser tuberosity serves as an attachment point for the subscapularis muscle, and even nondisplaced fractures can affect muscle function or joint stability during recovery.

Causes

Sequela fractures result from prior trauma, such as falls onto the shoulder, motor vehicle accidents, or high-impact injuries. The sequela phase reflects the long-term consequences of the initial fracture, where healing may be incomplete or associated with residual symptoms like pain or limited mobility.

Risk Factors

• Advanced age and osteoporosis, which reduce bone density and slow healing.
• Inadequate initial treatment or noncompliance with rehabilitation.
• Underlying conditions that impair bone healing, such as diabetes or vascular disease.

Symptoms

• Persistent pain in the shoulder or upper arm, often with activity.
• Reduced range of motion or stiffness in the shoulder joint.
• Muscle weakness or atrophy due to prolonged disuse.
• Occasional swelling or tenderness at the fracture site.

Diagnosis

Clinical evaluation focuses on assessing residual symptoms, range of motion, and functional limitations. Imaging, such as X-rays or MRIs, may be used to evaluate healing and identify any remaining structural issues. The diagnosis confirms the sequela phase by correlating with the history of the initial fracture and current clinical findings.

Treatment Options

Management may include physical therapy to restore strength and mobility, pain management, or assistive devices like slings. Surgical intervention is rare but may be considered for persistent instability or functional impairment. Treatment is tailored to the individual’s symptoms and functional goals.

Prognosis and Follow-Up

Prognosis is generally favorable, with most patients regaining near-normal function over time. Follow-up care focuses on monitoring recovery, addressing residual symptoms, and adjusting treatment as needed. Regular assessments help ensure optimal outcomes and prevent long-term complications.

Complications

• Chronic pain or stiffness that persists beyond expected healing time.
• Muscle weakness or atrophy due to prolonged disuse.
• Joint instability or reduced range of motion.
• Rarely, progression to arthritis or other degenerative changes.

Lifestyle & Prevention

• Engage in gradual, guided rehabilitation to restore strength and mobility.
• Avoid high-impact activities until cleared by a healthcare provider.
• Maintain bone health through proper nutrition and exercise to support healing.
• Use protective measures during activities with fall risk to prevent re-injury.

When to Seek Professional Help

Seek care if symptoms worsen, new pain or swelling develops, or functional limitations persist despite treatment. Prompt evaluation is important if numbness, tingling, or signs of infection (e.g., redness, fever) occur.

Tips for Medical Coders

Document the sequela phase clearly, including the history of the initial fracture and current residual effects. Ensure coding aligns with the ICD-10-CM guidelines for sequela (S codes) and specify the anatomical site (lesser tuberosity of humerus) and fracture status (nondisplaced). Verify that the encounter reflects ongoing management of the sequela rather than acute care.